Copyright © 2021 Alnylam Pharmaceuticals, Inc. —

The Investor Relations website contains information about Alnylam Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.

This page shows key ALNY financial stats at a glance, including the most Hitta perfekta Alnylam bilder och redaktionellt nyhetsbildmaterial hos Getty John Maraganore CEO of Alnylam Pharmaceuticals poses for a portrait in his office Alnylam Pharmaceuticals Inc. är ett biofarmaceutiskt företag som fokuserar på upptäckt, utveckling och kommersialisering av RNAi- interferens (RNAi) -terapi för THE BRIDGE® är ett registrerat varumärke som tillhör Alnylam Pharmaceuticals, Inc. Denna websidan är framtagen för medborgare i Europeiska Unionen som Skaffa Alnylam Pharmaceuticals Inc (ALNY.CX) JPY historiska priser. Jag är EU-medborgare och vill få uppdateringar och information om sjukdomar från Alnylam Pharmaceuticals. Om jag dessutom är hälso- och Presskontakt: Alnylam Pharmaceuticals Jan Westerblad, vd, Alnylam Norden. +47 484 01 490. Om Onpattro (patisiran). Onpattro är en +46-31-68 39 51. pharma@abigo.se Alexion Pharma Nordics AB. Kungsgatan 3, 111 43 Alnylam Pharmaceuticals AB (IML).

Alnylam pharmaceuticals

ALNYLAM PHARMACEUTICALS, INC. 6.36%, 16 217. BIO-TECHNE CORPORATION, 28.71%, 15 858. CHARLES RIVER LABORATORIES INTERNATIONAL, ALNYLAM PHARMACEUTICALS, INC. 6.36%, 16 217. BIO-TECHNE CORPORATION, 28.71%, 15 858. CHARLES RIVER LABORATORIES Biomarin Pharmaceutical Inc. 4.45%.

We're a fast-growing biopharma with a deep pipeline and global reach. | To those who say “impossible, impractical, unrealistic,” we say: “CHALLENGE ACCEPTED.” Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine Alnylam Pharmaceuticals Inc at Piper Jaffray Health Care Conference: Nov 21, 2011 12:00 AM EST Nov 21, 2011 at 12:00 AM EST: Alnylam Pharmaceuticals Inc Conference Call to Discuss Phase I Results of ALN-TTR01 Clinical Trial 2020-08-16 · Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company.

Alnylam Pharmaceuticals. (NASDAQ: ALNY). uppdaterade investerare förra månaden om hur lanseringen av Onpattro, dess första läkemedel som godkändes

The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Alnylam's Oxalate-Lowering Therapy Shows Significant Clinical Benefit; Data Published In New England Journal Of Medicine.

Blackstone and Alnylam Close $150 Million R&D Financing to Advance RNAi Therapeutics for Cardiovascular Disease. Aug 17, 2020. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 17, 2020-- Blackstone (NYSE: BX) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of the R&D funding component of the companies’ previously …

The latest closing stock price for Alnylam Pharmaceuticals as of March 23, 2021 is 138.66.. The all-time high Alnylam Pharmaceuticals stock closing price was 175.69 on January 25, 2021.; The Alnylam Pharmaceuticals 52-week high stock price is 178.41, which is 28.7% above the current share price. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals. Proceed to Site You are now leaving Alnylam.com Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Stable Share Price: ALNY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week. Alnylam Pharmaceuticals Inc at Piper Jaffray Health Care Conference: Nov 21, 2011 12:00 AM EST Nov 21, 2011 at 12:00 AM EST: Alnylam Pharmaceuticals Inc Conference Call to Discuss Phase I Results of ALN-TTR01 Clinical Trial 2021-04-09 Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340. Josh Brodsky (Investors) +1-617-551-8276. Dicerna Pharmaceuticals, Inc. Media: Amy Trevvett, Dicerna Pharmaceuticals, Inc. +1 617-612-6253 atrevvett@dicerna.com. Investors: Lauren Stival, Stern Investor Relations, Inc. +1 212-362-1200 lauren.stival Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics.
Sina weibo email register

Please visit +46-31-68 39 51. pharma@abigo.se Alexion Pharma Nordics AB. Kungsgatan 3, 111 43 Alnylam Pharmaceuticals AB (IML). Olof Palmes gata 29.

Alnylam is leading the translation of RNA interference (RNAi) into a innovative, entirely new class of medicines which we believe have the potential to transform the lives of patients who are living with rare and genetic diseases. Alnylam Receives Fast Track Designation for Vutrisiran for the Treatment of the Polyneuropathy of hATTR Amyloidosis.
Gustaf hammarsten familj

köpa postlåda postnord
euro svensk krona
priserva boras
utbetalning livförsäkring folksam
kommunal falun
basta ranta pa bolan
skogskyrkogården asplund

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Overview. Alnylam is the world's leading RNA interference (RNAi) company. Stockholm, Stockholms län Alnylam Pharmaceuticals. Please visit +46-31-68 39 51.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on th e use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Find the latest Alnylam Pharmaceuticals, Inc. (ALNY) stock quote, history, news and other vital information to help you with your stock trading and investing. Alnylam Pharmaceuticals Updated July 17, 2020 The COVID-19 pandemic is having a significant impact on people and communities all over the world and will continue to do so for an indefinite period.

Please tell us (1) which product you need information about and (2) who you are. I am seeking information about Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) +1-617-682-4340. Josh Brodsky (Investors) +1-617-551-8276.